Prednisone
MedicationCorticosteroid
Research strength: 3 / 5
MotherToBaby reports that prednisone or prednisolone is not expected to greatly increase the chance of birth defects. It notes older studies suggested a very small possible cleft lip or palate increase with first-trimester use, while newer studies and reviews have not confirmed it; two US case-control analyses found mixed results for corticosteroids as a group, not prednisone alone. ACOG reports the same mixed cleft findings and recommends oral prednisone, prednisolone, or methylprednisolone during pregnancy because the placenta converts them to relatively inactive forms. The product label reports cleft palate in animal studies, says controlled studies in pregnant women are lacking, and states use only if potential benefit justifies potential fetal risk. For rheumatic or musculoskeletal disease, ACR conditionally recommends continuing chronic prednisone below 10 mg daily if indicated and strongly recommends tapering higher doses to below 20 mg daily with a pregnancy-compatible medicine if needed. Ask your provider about your situation.
Last reviewed: 2026-10-16
Sources
- MotherToBaby: Prednisone/Prednisolone fact sheetTeratology service
- ACOG Committee Opinion No. 776: Immune Modulating Therapies in Pregnancy and LactationProfessional society
- DailyMed: Prednisone tablets, USP labelDrug company label
- American College of Rheumatology: 2020 reproductive health guideline, Appendix 12
- Carmichael et al., American Journal of Obstetrics and Gynecology 2007US government
- Skuladottir et al., Birth Defects Research 2014US government
Research strength: 3 / 5
MotherToBaby does not give a separate second-trimester birth-defect estimate. Its sheet says long-term oral corticosteroid use during pregnancy has been associated with preterm delivery and low birth weight, but the illness being treated may also contribute. A 2024 review found prednisone or prednisolone may be associated with lower gestational age, but did not find associations with miscarriage, stillbirth, or congenital abnormalities in the studies it reviewed. ACOG recommends oral prednisone, prednisolone, or methylprednisolone during pregnancy because the placenta converts them to relatively inactive forms, while noting the magnitude of possible long-term risks is unknown. For rheumatic or musculoskeletal disease, ACR conditionally recommends continuing chronic prednisone below 10 mg daily if indicated and strongly recommends tapering higher doses to below 20 mg daily with a pregnancy-compatible medicine if needed. Ask your provider about your situation.
Last reviewed: 2026-10-16
Sources
- MotherToBaby: Prednisone/Prednisolone fact sheetTeratology service
- ACOG Committee Opinion No. 776: Immune Modulating Therapies in Pregnancy and LactationProfessional society
- American College of Rheumatology: 2020 reproductive health guideline, Appendix 12
- Slob et al., Journal of Clinical Endocrinology and Metabolism 2024US government
Research strength: 3 / 5
MotherToBaby reports long-term oral corticosteroid use during pregnancy has been associated with preterm delivery and low birth weight, but the illness being treated may also contribute. In 528 pregnancies affected by rheumatoid arthritis, a 2020 observational study found prednisone-equivalent doses of at least 10 mg daily later in pregnancy were associated with a higher preterm birth rate; it cannot show that the medicine caused it. The product label says infants born to mothers who received substantial corticosteroid doses during pregnancy should be observed for signs of low adrenal hormone function. A 2017 series of 16 newborns after maternal prednisolone at 10 mg daily or more found no evidence of prolonged effects on the newborn adrenal hormone system, but the small series does not remove the label warning. ACOG recommends oral prednisone or prednisolone during pregnancy because the placenta converts them to relatively inactive forms, while noting the magnitude of possible long-term risks is unknown. Ask your provider about your situation.
Last reviewed: 2026-10-16
Sources
- MotherToBaby: Prednisone/Prednisolone fact sheetTeratology service
- Palmsten et al., Rheumatology 2020US government
- DailyMed: Prednisone tablets, USP labelDrug company label
- de Vetten et al., European Journal of Pediatrics 2017US government
- ACOG Committee Opinion No. 776: Immune Modulating Therapies in Pregnancy and LactationProfessional society
Prednisone — Breastfeeding
Research strength: 4 / 5
LactMed reports that prednisone levels in breast milk are very low and that no adverse effects have been reported in breastfed infants with maternal corticosteroid use generally. A small pharmacokinetic study measured milk from only two lactating participants and estimated relative infant doses of 0.35% to 0.58% for prednisone and 0.09% to 0.18% for prednisolone; it did not measure infant blood levels. MotherToBaby reports that prednisone and prednisolone pass into milk in small amounts and that high doses can temporarily reduce milk supply. For rheumatic or musculoskeletal disease, ACR says prednisone below 20 mg daily is compatible with breastfeeding and recommends delaying breastfeeding or discarding milk for four hours after doses above 20 mg daily. LactMed says a routine four-hour wait is not needed because milk levels are very low; the product label warns milk exposure could suppress growth, interfere with the infant's own corticosteroid production, or cause other effects, and says to decide whether to stop nursing or the drug based on the drug's importance to the mother. Ask your provider about your situation.
Last reviewed: 2026-10-16
Sources
- LactMed: PrednisoneUS government
- Ryu et al., Journal of Clinical Pharmacology 2018US government
- MotherToBaby: Prednisone/Prednisolone fact sheetTeratology service
- American College of Rheumatology: 2020 reproductive health guideline, Appendix 12
- DailyMed: Prednisone tablets, USP labelDrug company label
- NHS Specialist Pharmacy Service: Using oral or parenteral corticosteroids during breastfeedingUK government
Pregnancy
Most pregnancy outcome studies are observational, and many evaluate corticosteroids as a group rather than prednisone alone. For oral clefts, Carmichael et al. (2007) analyzed the US National Birth Defects Prevention Study, a case-control study with 1,141 cleft lip with or without cleft palate cases, 628 cleft palate-only cases, and 4,143 controls. Maternal corticosteroid use from 4 weeks before through 12 weeks after conception was reported for 33 CL/P cases (2.9%), 6 CP cases (1.0%), and 72 controls (1.7%); the odds ratio was 1.7 (95% CI 1.1 to 2.6) for CL/P and 0.5 (95% CI 0.2 to 1.3) for CP. A later NBDPS analysis by Skuladottir et al. (2014), with 2,372 cleft cases and 5,922 controls born in 2003 to 2009, found an overall association of 1.0 (95% CI 0.7 to 1.4) and little evidence of associations by corticosteroid component or timing. Both analyses relied on maternal telephone interviews, and neither established a prednisone-specific effect. MotherToBaby reports prednisone or prednisolone is not expected to increase miscarriage; a 2024 systematic review of antenatal predniso(lo)ne and dexamethasone found predniso(lo)ne may be associated with lower gestational age but was not associated with miscarriage, stillbirth, or congenital abnormalities in the reviewed studies. Palmsten et al. (2020) studied 528 rheumatoid arthritis pregnancies; later pregnancy oral corticosteroid doses of at least 10 mg prednisone equivalent per day were associated with preterm birth rate (aHR 2.45, 95% CI 1.32 to 4.56) compared with no oral corticosteroid dose. The study was observational and disease-specific, so the association does not establish that the medication caused the outcome. DailyMed labeling says infants born after substantial maternal corticosteroid exposure should be observed for signs of hypoadrenalism. In a 2017 case series of 16 newborns after maternal prednisolone at 10 mg per day or more, researchers found no evidence of prolonged effects on the newborn hypothalamic-pituitary-adrenal system; the small series does not remove the label warning. ACOG says long-term glucocorticoid treatment may increase several maternal and fetal risks, but states the magnitude of these possible risks is not known.
Breastfeeding
MotherToBaby and LactMed report no adverse effects in infants in the reports they summarize, but this does not provide a prednisone-specific effect estimate. Ryu et al. (2018) studied prednisone and prednisolone pharmacokinetics in 19 women across pregnancy and postpartum; breast milk was collected from two lactating participants. Relative infant doses were 0.35% and 0.58% for prednisone and 0.09% and 0.18% for prednisolone. Drug concentrations in milk were below assay detection after 12 hours for prednisone and 6 hours for prednisolone. The study measured drug levels, not infant serum levels or clinical infant outcomes. MotherToBaby also reports small milk amounts and possible temporary supply reduction at high doses. LactMed says a routine four-hour wait is unnecessary because milk levels are very low, while ACR recommends a four-hour delay or discarding milk after prednisone doses above 20 mg daily for people with rheumatic or musculoskeletal disease.
MotherToBaby says prednisone and prednisolone are corticosteroids and that the body breaks prednisone down into prednisolone. Prednisone tablets contain prednisone as the active ingredient; the cited DailyMed label is for generic prednisone tablets from A-S Medication Solutions.
What was tested
Carmichael and Skuladottir used telephone interviews in separate waves of the US National Birth Defects Prevention Study and assessed corticosteroids as a class. Palmsten studied 528 pregnancies affected by rheumatoid arthritis using interviews and medical records; disease activity and treatment indication can affect pregnancy outcomes. Slob et al. reviewed 15 eligible studies and searched human evidence through August 2022. de Vetten was a single-center case series of 16 newborns exposed to maternal prednisolone, not prednisone alone. Ryu measured blood, urine, cord blood, and milk levels in 19 participants overall, but milk samples came from two lactating participants; it did not measure infant serum levels. ACR dose recommendations are scoped to rheumatic and musculoskeletal disease, and the ACOG Committee Opinion addresses immune-modulating therapies.
Do human studies show an increased cleft risk with early pregnancy corticosteroid use?
- Source A says
- MotherToBaby says older studies suggested a very small possible increase in cleft lip or palate with first-trimester use. Carmichael et al. reported an association between early corticosteroid exposure and cleft lip with or without palate (OR 1.7, 95% CI 1.1 to 2.6). The product label reports cleft palate in animal studies. (MotherToBaby: Prednisone/Prednisolone fact sheet, Carmichael et al., American Journal of Obstetrics and Gynecology 2007, DailyMed: Prednisone tablets, USP label (A-S Medication Solutions))
- Source B says
- The later 2003 to 2009 NBDPS analysis found no overall association (OR 1.0, 95% CI 0.7 to 1.4) and little evidence by corticosteroid component or timing. ACOG says more recent data have failed to demonstrate an association. (Skuladottir et al., Birth Defects Research 2014, ACOG Committee Opinion No. 776: Immune Modulating Therapies in Pregnancy and Lactation)
- Why they differ
- The earlier NBDPS analysis used 1997 to 2002 data and had fewer exposed cases; the later analysis more than doubled the study population with 2003 to 2009 births. Both relied on maternal telephone interviews and combined different corticosteroids, so neither isolates prednisone well.
- What the evidence shows overall
- The human findings are mixed and concern corticosteroids as a class, not prednisone alone. ACOG and MotherToBaby describe the early cleft signal as unconfirmed by newer data. Animal findings in the label should remain separate from human findings, and the label warning should not be presented as proof of a human effect.
Is a four-hour wait after prednisone needed before breastfeeding?
- Source A says
- LactMed says a routine four-hour wait is not necessary because prednisone milk levels are very low. MotherToBaby says waiting can limit milk exposure but is not necessary for everyone. (LactMed: Prednisone, MotherToBaby: Prednisone/Prednisolone fact sheet)
- Source B says
- For people with rheumatic or musculoskeletal disease, ACR strongly recommends delaying breastfeeding or discarding milk for four hours after prednisone doses above 20 mg daily. The product label warns of possible serious adverse reactions in nursing infants and says to decide whether to discontinue nursing or the drug based on the drug's importance to the mother. (American College of Rheumatology: 2020 reproductive health guideline, Appendix 12, DailyMed: Prednisone tablets, USP label (A-S Medication Solutions))
- Why they differ
- LactMed focuses on measured milk levels and limited infant outcome reports. ACR's dose-specific recommendation is scoped to rheumatic and musculoskeletal disease and aims to reduce exposure around expected peak milk levels; the product label uses broader cautionary language.
- Other sources
- The NHS Specialist Pharmacy Service says corticosteroids can be used during breastfeeding but notes very limited information, recommends the lowest dose and duration possible, and advises avoiding prolonged high-dose treatment where possible or monitoring infant adrenal function if it is unavoidable. Its recommendations apply to full-term, healthy infants. (NHS Specialist Pharmacy Service: Using oral or parenteral corticosteroids during breastfeeding)
- What the evidence shows overall
- Ryu et al. measured milk from two lactating participants, so direct milk-level evidence remains limited and does not establish clinical infant outcomes. LactMed's no-routine-wait position and ACR's high-dose, disease-specific four-hour recommendation should both remain visible rather than being generalized as one universal rule.
- ACOG Committee Opinion No. 776 recommends oral prednisone, prednisolone, or methylprednisolone during pregnancy because the human placenta converts them to relatively inactive forms. The opinion addresses immune-modulating therapies. (ACOG)
- For rheumatic and musculoskeletal disease, ACR conditionally recommends continuing chronic prednisone below 10 mg daily during pregnancy if clinically indicated. It strongly recommends tapering higher non-fluorinated steroid doses to below 20 mg daily with a pregnancy-compatible immunosuppressive agent if needed. (American College of Rheumatology)
- For rheumatic and musculoskeletal disease, ACR strongly considers prednisone below 20 mg daily compatible with breastfeeding and recommends delaying breastfeeding or discarding milk for four hours after doses above 20 mg daily. (American College of Rheumatology)
- LactMed says a routine four-hour wait before breastfeeding is not necessary because prednisone milk levels are very low. (LactMed)
- The NHS Specialist Pharmacy Service says corticosteroids can be used during breastfeeding, recommends the lowest dose and duration possible, and limits its recommendations to full-term, healthy infants. It advises avoiding prolonged high-dose therapy where possible and monitoring infant adrenal function if such use is unavoidable. (NHS Specialist Pharmacy Service)
General research, not specific to pregnancy.
Outside pregnancy, the product label warns that prednisone suppresses immune function and can increase infection risk. It also warns against abrupt discontinuation after prolonged treatment because adrenal insufficiency can result.
- The label says prednisone tablets are contraindicated in systemic fungal infections and known hypersensitivity to components. (DailyMed: Prednisone tablets, USP label (A-S Medication Solutions))
- The label says corticosteroids, including prednisone, suppress the immune system and increase the risk of infection with any pathogen; infectious complications can be severe and sometimes fatal, and their rate increases with higher doses. (DailyMed: Prednisone tablets, USP label (A-S Medication Solutions))
- The label warns patients not to stop corticosteroids abruptly or without medical supervision; too-rapid withdrawal after prolonged treatment may cause adrenal insufficiency, and gradual dose reduction may minimize it. (DailyMed: Prednisone tablets, USP label (A-S Medication Solutions))
- MotherToBaby: Prednisone/Prednisolone fact sheetTeratology serviceSecondary
- LactMed: PrednisoneUS governmentSecondaryPage dated 2024-04-15Independent check
- DailyMed: Prednisone tablets, USP label (A-S Medication Solutions)Drug company labelTertiaryPage dated 2024-06-01
- ACOG Committee Opinion No. 776: Immune Modulating Therapies in Pregnancy and LactationProfessional societySecondaryPage dated 2019-04-01Independent check
- American College of Rheumatology: 2020 reproductive health guideline, Appendix 12Secondary
- NHS Specialist Pharmacy Service: Using oral or parenteral corticosteroids during breastfeedingUK governmentSecondaryPage dated 2023-07-17Independent check
- Carmichael et al., American Journal of Obstetrics and Gynecology 2007US governmentPrimaryIndependent check
- Skuladottir et al., Birth Defects Research 2014US governmentPrimaryIndependent check
- Palmsten et al., Rheumatology 2020US governmentPrimaryIndependent check
- Slob et al., Journal of Clinical Endocrinology and Metabolism 2024US governmentPrimaryIndependent check
- de Vetten et al., European Journal of Pediatrics 2017US governmentPrimaryIndependent check
- Ryu et al., Journal of Clinical Pharmacology 2018US governmentPrimaryIndependent check
Last reviewed 2026-10-16
Independent check 2026-10-16
Not yet clinician-reviewed
Ask your provider about your situation.
Similar medications
- Prednisolone
- Methylprednisolone